eszopiclone + venlafaxine

**eszopiclone + venlafaxine** is a non-fixed-dose combination of two approved small-molecule oral drugs used together off-label or in research settings. **Eszopiclone** is a non-benzodiazepine hypnotic (classified as a cyclopyrrolone) that acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABAA) receptor to promote sleep. **Venlafaxine** is a serotonin-norepinephrine reuptake inhibitor (SNRI) class antidepressant that modulates serotonergic and noradrenergic neurotransmitter levels. This combination has been studied for two primary indications: 1. As part of triple therapy with acetazolamide for **obstructive sleep apnea (OSA)**, where each drug targets a different pathogenic mechanism (i.e., sleep fragmentation, upper airway muscle tone, arousal threshold)[1][2][3][4][7]. 2. As co-therapy in patients with **major depressive disorder and comorbid insomnia**[5]. In OSA trials, eszopiclone + venlafaxine may attenuate OSA severity, particularly in patients who do not fully respond to eszopiclone alone; however, the evidence is limited and benefit of the combination over dual therapy is not established[1][2][3].